Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) rose 2.1% during mid-day trading on Monday . The company traded as high as $0.83 and last traded at $0.83. Approximately 81,173 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 216,034 shares. The stock had previously closed at $0.81.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the company. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price target on the stock. D. Boral Capital restated a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, January 15th. Finally, Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $6.33.
Get Our Latest Stock Report on CNTX
Context Therapeutics Stock Up 9.6 %
The stock has a fifty day moving average price of $0.96 and a 200-day moving average price of $1.63. The firm has a market cap of $66.57 million, a price-to-earnings ratio of -0.98 and a beta of 2.06.
Institutional Trading of Context Therapeutics
Several hedge funds have recently made changes to their positions in the company. MPM Bioimpact LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth about $15,441,000. Blue Owl Capital Holdings LP boosted its holdings in Context Therapeutics by 17.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock valued at $6,676,000 after purchasing an additional 946,638 shares in the last quarter. Franklin Resources Inc. increased its position in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after purchasing an additional 2,149,392 shares during the period. Allostery Investments LP purchased a new position in shares of Context Therapeutics during the 4th quarter worth approximately $998,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Context Therapeutics by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock valued at $661,000 after buying an additional 52,830 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
